Michael D. Pak

Array ( [id] => 17141685 [patent_doc_number] => 20210309697 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CD40-MEDIATED DISEASES [patent_app_type] => utility [patent_app_number] => 17/221182 [patent_app_country] => US [patent_app_date] => 2021-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14210 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17221182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17383949 [patent_doc_number] => 20220031801 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST [patent_app_type] => utility [patent_app_number] => 17/199733 [patent_app_country] => US [patent_app_date] => 2021-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19246 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17199733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067327 [patent_doc_number] => 20210269542 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => ANTI-GITR ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/197547 [patent_app_country] => US [patent_app_date] => 2021-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50523 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17197547 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356829 [patent_doc_number] => 20220017625 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => TUMOR-SPECIFIC ANTI-EGFR ANTIBODY AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/182956 [patent_app_country] => US [patent_app_date] => 2021-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17182956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19931742 [patent_doc_number] => 12304939 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-20 [patent_title] => EGFR and C-met fibronectin type III domain binding molecules [patent_app_type] => utility [patent_app_number] => 17/174524 [patent_app_country] => US [patent_app_date] => 2021-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 10 [patent_no_of_words] => 31706 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17174524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19638597 [patent_doc_number] => 12169202 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-17 [patent_title] => Measurement of 2-hydroxyglutarate enantiomer levels as a biomarker for IDH mutant cancers [patent_app_type] => utility [patent_app_number] => 17/172940 [patent_app_country] => US [patent_app_date] => 2021-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 16 [patent_no_of_words] => 10334 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17172940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356790 [patent_doc_number] => 20220017586 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => EXPOSED COLLAGEN-TARGETED FUSION CYTOKINE FOR IMMUNE MODULATION IN INVASIVE CANCERS AND LESIONS OF INFECTIONS [patent_app_type] => utility [patent_app_number] => 17/152439 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10880 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17152439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16917678 [patent_doc_number] => 20210190770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => COMPOSITIONS AND METHODS FOR USING FIXED BIOLOGICAL SAMPLES IN PARTITION-BASED ASSAYS [patent_app_type] => utility [patent_app_number] => 17/131174 [patent_app_country] => US [patent_app_date] => 2020-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36382 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17131174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18312807 [patent_doc_number] => 20230116707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => DETECTION OF NOVEL DEGRADATION-RELATED INTERACTIONS [patent_app_type] => utility [patent_app_number] => 17/785676 [patent_app_country] => US [patent_app_date] => 2020-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14824 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -72 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17785676 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762692 [patent_doc_number] => 20210108273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => Compositions And Methods For Treating Or Preventing Prostate Cancer And For Detecting Androgen Receptor Variants [patent_app_type] => utility [patent_app_number] => 17/117435 [patent_app_country] => US [patent_app_date] => 2020-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25763 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17117435 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18140124 [patent_doc_number] => 20230013963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => REVERSIBLE CELL DETECTION VIA MHC WITH CONJUGATES HAVING AN ENZYMATICALLY CLEAVABLE DETECTION MOIETY [patent_app_type] => utility [patent_app_number] => 17/782172 [patent_app_country] => US [patent_app_date] => 2020-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13636 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16848194 [patent_doc_number] => 20210148939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => METHODS FOR SCREENING FOR BINDING PARTNERS OF G-PROTEIN COUPLED RECEPTORS [patent_app_type] => utility [patent_app_number] => 17/107617 [patent_app_country] => US [patent_app_date] => 2020-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46908 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17107617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18887977 [patent_doc_number] => 11866742 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-09 [patent_title] => Fusion proteins comprising enzyme replacement therapy enzymes [patent_app_type] => utility [patent_app_number] => 17/102138 [patent_app_country] => US [patent_app_date] => 2020-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 30 [patent_no_of_words] => 51569 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17102138 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093124 [patent_doc_number] => 20220411465 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => ELUATE COLLECTION DURING ANTIBODY CHROMATOGRAPHY [patent_app_type] => utility [patent_app_number] => 17/777366 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17777366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093124 [patent_doc_number] => 20220411465 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => ELUATE COLLECTION DURING ANTIBODY CHROMATOGRAPHY [patent_app_type] => utility [patent_app_number] => 17/777366 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17777366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17044949 [patent_doc_number] => 11098117 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-24 [patent_title] => Anti-CD137 antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/094196 [patent_app_country] => US [patent_app_date] => 2020-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 37 [patent_no_of_words] => 49475 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17094196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19473889 [patent_doc_number] => 12103965 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-01 [patent_title] => Diagnostic kit [patent_app_type] => utility [patent_app_number] => 17/089321 [patent_app_country] => US [patent_app_date] => 2020-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 82 [patent_no_of_words] => 9048 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17089321 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621570 [patent_doc_number] => 20210040223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => Antibodies to Canine Interleukin-4 Receptor Alpha [patent_app_type] => utility [patent_app_number] => 17/081188 [patent_app_country] => US [patent_app_date] => 2020-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31978 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17081188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19521121 [patent_doc_number] => 12122829 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-22 [patent_title] => Human alpha-folate receptor chimeric antigen receptor [patent_app_type] => utility [patent_app_number] => 17/076359 [patent_app_country] => US [patent_app_date] => 2020-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 25841 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17076359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16781443 [patent_doc_number] => 20210118522 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => METHODS AND COMPOSITION FOR MODULATING IMMUNE RESPONSE AND IMMUNE HOMEOSTASIS [patent_app_type] => utility [patent_app_number] => 17/072934 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91757 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17072934 [rel_patent_id] =>[rel_patent_doc_number] =>)